Elekta AB (OTCMKTS:EKTAY) Short Interest Down 66.7% in July

Key Points

• Short interest in Elekta AB (OTCMKTS:EKTAY) has decreased by 66.7%, with only 100 shares short sold as of July 15th, significantly down from 300 shares at the end of June.
• For the last quarter, Elekta reported an earnings per share (EPS) of $0.11, which fell short of the consensus estimate of $0.13, indicating lower than expected performance.
• Analysts from Danske have lowered Elekta's rating to "hold," reflecting a cautious outlook on the stock's future performance.

Elekta AB (OTCMKTS:EKTAY - Get Free Report) was the recipient of a large drop in short interest in July. As of July 15th, there was short interest totaling 100 shares, adropof66.7% from the June 30th total of 300 shares. Currently,0.0% of the shares of the stock are sold short. Based on an average daily volume of 5,600 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily volume of 5,600 shares, the days-to-cover ratio is presently 0.0 days. Currently,0.0% of the shares of the stock are sold short.

Elekta Trading Down 1.7%

OTCMKTS:EKTAY traded down $0.08 during mid-day trading on Friday, reaching $4.78. The company's stock had a trading volume of 4,057 shares, compared to its average volume of 4,994. The company's fifty day simple moving average is $5.05 and its two-hundred day simple moving average is $5.29. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.09 and a quick ratio of 0.86. Elekta has a twelve month low of $4.36 and a twelve month high of $7.13. The stock has a market cap of $1.83 billion, a P/E ratio of 95.58 and a beta of 1.19.

Elekta (OTCMKTS:EKTAY - Get Free Report) last issued its quarterly earnings results on Wednesday, May 28th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.13 by ($0.02). Elekta had a return on equity of 11.55% and a net margin of 1.15%. The business had revenue of $503.22 million during the quarter, compared to analyst estimates of $507.19 million. On average, equities analysts predict that Elekta will post 0.36 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Danske cut Elekta to a "hold" rating in a research report on Tuesday, June 3rd.

Elekta Company Profile

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.